Modality
Radioligand
MOA
JAK1/2i
Target
WEE1
Pathway
Autophagy
ASPancreatic Ca
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
May 2019
→ Nov 2029
Phase 1Current
NCT05824303
141 pts·AS
2019-05→2029-11·Recruiting
141 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-11-183.6y awayPh2 Data· AS
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Recruit…
Catalysts
Ph2 Data
2029-11-18 · 3.6y away
AS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05824303 | Phase 1/2 | AS | Recruiting | 141 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Fixanesiran | AbbVie | Preclinical | RET | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 |